Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA topoisomerase IV is an essential bacterial enzyme that plays a critical role in managing DNA supercoiling and unlinking intertwined daughter chromosomes (decatenation) during DNA replication (UniProt P0A7G6; PMID: 9293187). It is a heterotetrameric Type II topoisomerase consisting of two ParC subunits and two ParE subunits. The ParE subunit (also known as subunit B) contains the ATP-binding domain and provides the energy required for the enzyme's catalytic cycle through ATP hydrolysis (UniProt P0A7G6; PMID: 24597508). This enzyme is a primary target for the fluoroquinolone class of antibiotics, which interfere with the DNA ligation step, resulting in the accumulation of double-strand DNA breaks and subsequent bacterial cell death (PMID: 9371354; PMID: 24597508). Resistance to these antibiotics frequently arises through specific mutations in the ParE or ParC subunits that reduce drug binding affinity (PMID: 24597508). Topoisomerase IV is distinct from DNA gyrase, although both are Type II topoisomerases and share structural and functional similarities (PMID: 9293187).
Fluoroquinolones stabilize the covalent enzyme-DNA cleavage complex, preventing DNA religation and causing double-strand breaks (PMID: 9293187, 24597508). Aminocoumarins inhibit the ATPase activity of the ParE subunit by competing with ATP binding (PMID: 9293187).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA topoisomerase 4 subunit B (ParE) (ParE).